Cargando…
ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study
BACKGROUND: Previous studies showed that the combination of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector and potentiator, lumacaftor–ivacaftor (LUMA–IVA) provides meaningful clinical benefits in patients with cystic fibrosis who are homozygous for the Phe508del CFTR mutation....
Autores principales: | Arooj, Parniya, Morrissy, David V, McCarthy, Yvonne, Vagg, Tamara, McCarthy, Mairead, Fleming, Claire, Daly, Mary, Eustace, Joseph A, Murphy, Desmond M, Plant, B J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163494/ https://www.ncbi.nlm.nih.gov/pubmed/37130650 http://dx.doi.org/10.1136/bmjresp-2022-001590 |
Ejemplares similares
-
Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
por: Higgins, Mark, et al.
Publicado: (2023) -
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018) -
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
por: Clancy, J P, et al.
Publicado: (2013) -
Utility and validity of dynamic chest radiography in cystic fibrosis (dynamic CF): an observational, non-controlled, non-randomised, single-centre, prospective study
por: FitzMaurice, Thomas Simon, et al.
Publicado: (2020) -
Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
por: Almulhem, Maryam, et al.
Publicado: (2022)